Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1 1

Status

Recruiting 6Active not recruiting 6Completed 1

Sponsor Class

OTHER 5NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 5Prostate Adenocarcinoma 1

Interventions

Specimen Handling 321Magnetic Resonance Spectroscopy 275pembrolizumab 267Carboplatin 190Cyclophosphamide 185Biopsy 178Cisplatin 164Gemcitabine 139Paclitaxel 137Bevacizumab 123fludarabine 122Nivolumab 117Radiotherapy 113Oxaliplatin 94venetoclax 92Docetaxel 90Fluorouracil 88Capecitabine 88Dexamethasone 85Drug Therapy 76Pemetrexed 75Rituximab 73durvalumab 71Leucovorin 71Blood Specimen Collection 70Radiosurgery 69Standard of Care 67atezolizumab 64Doxorubicin 64Radiation 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × luprolide acetate gel depot × 90 days × Clear all
NCT04423211 2026-05-15

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Eastern Cooperative Oncology Group

Phase 3 Recruiting
804 enrolled
Genitourinary

Prostatic Neoplasms

NCT06305598 2026-05-15

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Roswell Park Cancer Institute

Phase 1 Recruiting
14 enrolled
Genitourinary

Prostatic Neoplasms

NCT07455903 2026-05-13

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Baptist Health South Florida

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostatic Neoplasms

NCT05873192 2026-05-05

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT06654336 2026-03-13

RATIONAL

Ontario Clinical Oncology Group (OCOG)

Phase 2 Recruiting
162 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT07142551 2026-03-11

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
60 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡